Benefits
Improved lipid profile in hyperlipidemia
Bumrungpert 2018 (PMID 29865227, n=48 hyperlipidemic adults, 6 weeks, double-blind RCT) showed 1,000 mg/day ferulic acid significantly reduced: total cholesterol (-8.1%, p<0.001), LDL-c (-9.3%, p<0.001), triglycerides (-12.1%, p=0.001), and oxidized LDL (-7.1%, p=0.002) vs placebo. HDL-c increased modestly. Magnitude approaches that of low-intensity statin therapy.
Reduced inflammatory markers
Same Bumrungpert 2018 trial: hs-CRP reduced by 32.66% (p<0.001) and TNF-α reduced by 13.06% (p<0.001) in ferulic acid group vs placebo. Effect size on hs-CRP is comparable to moderate-dose statin therapy and may explain some of the cardiovascular protective potential beyond simple lipid lowering.
Antioxidant activity in vivo
Ferulic acid increases plasma total antioxidant capacity, reduces malondialdehyde (lipid peroxidation marker), and decreases protein carbonyl content. The methoxy-phenolic structure efficiently scavenges peroxyl radicals and chelates transition metals. Combined oral and topical use produces synergistic antioxidant effects in the C E Ferulic skin formulation.
Skin photoprotection (topical)
Topical 0.5% ferulic acid combined with 15% vitamin C and 1% vitamin E (SkinCeuticals C E Ferulic formulation) produces 8-fold greater UV photoprotection than vitamin C alone. The classic Pinnell 2005 paper established this synergy. Reduces UV-induced erythema, sunburn cell formation, and DNA damage. Now a standard ingredient in dermatological serums.
Anti-hypertensive effect (mechanistic, modest clinical)
Multiple animal studies (Suzuki PMID 11924733, 17485012; Alam 2013 PMID 23188120) consistently show ferulic acid reduces blood pressure in hypertensive rat models via NO/eNOS upregulation. Limited but suggestive human evidence — γ-oryzanol (ferulate ester) trials in T2D show modest BP reduction. Direct human ferulic acid hypertension trials still lacking.
Mechanism of action
Direct free radical scavenging
The phenolic hydroxyl group at the 4-position donates hydrogen to scavenge peroxyl, hydroxyl, superoxide, and other radicals. The methoxy group at the 3-position stabilizes the resulting phenoxyl radical via resonance. The α,β-unsaturated carboxylic acid extends conjugation, contributing further antioxidant capacity. Stronger antioxidant per molecule than classical phenolic antioxidants in oil-soluble systems.
Nrf2/ARE pathway activation
Ferulic acid induces nuclear factor erythroid-2-related factor 2 (Nrf2) translocation and binding to antioxidant response elements (ARE), upregulating endogenous antioxidant enzymes (HO-1, NQO1, glutathione synthesis enzymes). This 'indirect' antioxidant mechanism produces longer-lasting cellular protection than direct radical scavenging alone.
NF-κB inhibition (anti-inflammatory)
Ferulic acid suppresses NF-κB signaling, reducing transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and adhesion molecules. Mechanistic basis for the hs-CRP and TNF-α reductions observed in Bumrungpert 2018.
eNOS upregulation and vascular smooth muscle effects
In hypertensive animal models, ferulic acid increases endothelial nitric oxide synthase (eNOS) expression and activity, enhancing NO bioavailability and producing vasodilation. May also modulate vascular smooth muscle calcium channels. These mechanisms underlie observed BP reductions in hypertensive (but not normotensive) animals.
Clinical trials
Randomized, double-blind, placebo-controlled clinical trial (Bumrungpert A, Lilitchan S, Tuntipopipat S, Tirawanchai N, Komindr S 2018, Nutrients 10(6):713, doi:10.3390/nu10060713).
48 adults with hyperlipidemia. Randomized to 1,000 mg/day ferulic acid (n=24) or placebo (n=24) for 6 weeks. Lipid profiles, oxidative stress markers (oxidized LDL, MDA, TAC), and inflammatory markers (hs-CRP, TNF-α) measured at baseline and end.
Ferulic acid group showed significant improvements vs placebo: total cholesterol -8.1% (p<0.001), LDL-c -9.3% (p<0.001), triglycerides -12.1% (p=0.001), oxidized LDL -7.1% (p=0.002), hs-CRP -32.66% (p<0.001), TNF-α -13.06% (p<0.001). HDL-c increased modestly. No significant adverse events reported. Authors concluded ferulic acid has potential to reduce cardiovascular disease risk factors via combined lipid-, oxidative stress-, and inflammation-lowering effects.
Mechanistic crossover study (Suzuki A, Yamamoto M, Jokura H, Fujii A, Tokimitsu I, Hase T, Saito I 2007, Am J Hypertens 20(5):508-513, doi:10.1016/j.amjhyper.2006.11.008).
Mildly hypertensive subjects evaluated for acute effects of ferulic acid intake on blood pressure parameters and endothelial function.
Confirmed translation of preclinical antihypertensive findings to humans at the mechanistic level — improved endothelial function and modest BP reduction. Provided rationale for further clinical investigation of ferulic acid in cardiovascular indications.
Photoprotection study (Pinnell SR, Yang H, Omar M, Monteiro-Riviere N, DeBuys HV, Walker LC, Wang Y, Levine M 2005, Dermatol Surg 31(7 Pt 2):814-7, PMID 16029672 — referenced by SkinCeuticals C E Ferulic).
Topical application of 0.5% ferulic acid + 15% L-ascorbic acid + 1% α-tocopherol vs comparator formulations on human skin with subsequent UV exposure.
Ferulic acid increased UV photoprotection of vitamins C and E approximately 8-fold. Reduced UV-induced erythema, sunburn cell formation, and thymine dimer (DNA damage marker) formation. Established the foundation for dermatological serums combining these ingredients. Topical effect distinct from oral systemic effects.
About this ingredient
Ferulic acid (FA, IUPAC: (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid) is a hydroxycinnamic acid — caffeic acid with a methylated 3-hydroxy group. It is one of the most abundant phenolic acids in plants, particularly concentrated in cell wall components (covalently bound to arabinoxylans and lignin) of cereals (rice bran ~600 mg/100g, oat bran ~300 mg/100g, wheat bran ~200 mg/100g), as well as in Angelica sinensis (dong quai), Cimicifuga racemosa (black cohosh), Ferula assa-foetida, and Rhizoma Ligustici (ligusticum chuanxiong). γ-Oryzanol (rice bran extract) is a mixture of ferulic acid esters with sterols and triterpene alcohols — most ferulate clinical effects in rice bran trials are attributed to γ-oryzanol's hydrolyzed ferulate.
Commercial supplements typically use synthetic ferulic acid (~99% purity) or rice bran-derived γ-oryzanol. Also widely used in cosmetic formulations (SkinCeuticals C E Ferulic, La Roche-Posay) at 0.5-1.0% topical concentration. EVIDENCE: 3/5 reflects: (1) one strong human RCT (Bumrungpert 2018 PMID 29865227) showing meaningful improvements across lipid, oxidative stress, and inflammatory markers in hyperlipidemic adults, (2) multiple supportive trials of ferulate-rich foods (γ-oryzanol, rice bran) showing similar effects, (3) extensive preclinical mechanistic literature, (4) well-established topical photoprotection efficacy.
Limited by relative paucity of large/long-duration human cardiovascular outcome trials. SAFETY: Excellent tolerability across published trials. Topical use widely accepted in cosmetic dermatology.
Best positioned as: (a) cardiovascular adjunct for those with hyperlipidemia or metabolic syndrome (1 g/day), (b) topical antioxidant in combination serums for skin photoprotection, (c) intake from food sources (whole grains, especially rice bran, popcorn, oats) as part of polyphenol-rich diet. The Bumrungpert trial outcomes — particularly the 32% hs-CRP reduction — make this an interesting cardiovascular candidate, though larger trials in different populations are needed for stronger evidence.